Drug intelligence / Profile preview

Lipovax-MM

Development stage: Unknown
Lead developer: Lipotek
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

Lipovax-MM is a liposome-based therapeutic vaccine developed by Lipotek, in partnership with Synamtix Ltd, for the treatment of multiple myeloma. It utilizes the proprietary Lipovax platform, which employs liposomes to deliver tumor-associated antigens to the immune system. The goal of the therapy is to stimulate a targeted anti-tumor immune response by enhancing antigen presentation to T-cells. As of 2016, the program was reported to be in Phase 1 clinical trials.

Other names: Lipovax-MMLipovaxs-MM

Targets

DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)

Beyond the preview

Go deeper on Lipovax-MM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipovax-MM.

Explore the full profile